SOURCE: NeuroInvestment

February 05, 2007 09:00 ET

Parkinson's Therapeutics Reviewed by NeuroInvestment

CARDIFF, CA -- (MARKET WIRE) -- February 5, 2007 -- NI Research has released the February issue of NeuroInvestment, which reviews the status and prospects of Parkinson's therapeutics. Parkinson's is estimated to affect 1.5 million Americans, and with the aging population, its prevalence is likely to double in the next few decades. While the initial treatment of Parkinson's with levodopa is a relative success story for neurology, the fact is that current treatments for Parkinson's are either only temporary in nature, with symptoms becoming even more virulent after five years, or are only partially effective.

This review covers both potential improvements in the compensatory treatments currently available, and next-generation neuroprotective and neuroregenerative therapies in development. There are improved delivery options from UCB Pharma, Amarin, and earlier on, such companies as NuPathe. Adjunctive drug therapies include compounds from Serono/Newron, Neurogen, and Acadia (NASDAQ: ACAD). Possible neuroprotectants are in development by Biogen-Idec, Neurocrine Biosciences (NASDAQ: NBIX), Avicena, Allon Therapeutics, Lilly, NeuroNova, and Amarin. Cutting-edge cell and gene therapy approaches are being developed by such companies as Schering/Titan, Ceregene, Neurologix, Genzyme, and Oxford Biomedica.

The February NeuroInvestment also takes a closer look at such topics as Acadia Pharmaceuticals' ACP-104, D-Pharm, Vanda, and Cephalon, with a full review of Faust Pharmaceuticals. The latest information regarding the improved prospects for Cortex Pharmaceuticals (AMEX: COR) and its development of CX717 for ADHD is included.

This follows in the wake of the January NI overview of the CNS sector, which assessed the high and lowpoints of 2006, prospects for 2007, including commentary on Vanda Pharmaceuticals and a full review of Torrey Pines Therapeutics.

About NeuroInvestment: NeuroInvestment is the independent, monthly review of the neurotherapeutics area. A one-year corporate subscription is $1500, email or hardcopy. Add $250 for dual delivery, add $40 for airmail delivery outside North America. A three-month trial subscription is US$450.

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroInvestment since 1995, the Private CNS Company Review since 2003, and provides inlicensing consultation and custom research for large and small pharmaceutical firms. NI Research has developed an unmatched information base regarding both publicly and privately held neuro-oriented companies.

Contact Information